How do you use the biopsy add-on codes 11102 to 11107 correctly?

Which biopsy code is the primary when you do more than one on the same day?

Only one primary biopsy code may be reported per patient per date of service, and it is the highest valued one performed. Every other lesion goes on an add-on code matched to the technique used on that lesion. The ranking never changes: incisional 11106 outranks punch 11104, which outranks tangential 11102.

The rule, as stated in the AAFP guidance built on the CPT instructions: when multiple biopsies are performed for the same patient on the same date, only one primary biopsy code may be reported. Same technique, report the primary code with the highest relative value units and the corresponding add-on for the rest. Different techniques, report the highest valued primary, then the add-on specific to each of the other biopsies performed. The primary code goes on the claim without a modifier.

That last sentence is where claims come apart. Coders trained on the pre-2019 codes reach for a modifier out of habit, or report the first lesion in the note as the primary because it is first. Note order is irrelevant. Relative value order decides.

How to report four lesions and three techniques

A patient presents with four suspicious lesions. The physician takes one wedge from the back, one punch from the forearm and two shaves from the shoulder.

1. Rank the techniques performed. Incisional was performed, so 11106 is the primary. One unit, no modifier.
2. Take the remaining three lesions and assign each an add-on matched to its own technique. The forearm punch becomes 11105. The two shoulder shaves become 11103.
3. Set the units. 11105 gets one unit. 11103 gets two units, because the descriptor reads each separate or additional lesion.
4. Submit 11106 x1, 11105 x1, 11103 x2. No modifier 51, no modifier 59 on the add-ons.

Note what is not on that claim: 11104, and a second 11106. Once the incisional biopsy takes the primary slot, no other parent code from this range belongs on the same date. Ranking and units on a session like this is ordinary surgical coding work done against the current descriptors.

What do the biopsy CPT codes 11102 to 11107 actually cover?

Six codes, three techniques, three add-ons. They are defined by the method used to obtain the tissue, not by the location of the lesion and not by its size. That is why a size measurement is irrelevant to code selection here while it decides everything on an excision.

The descriptors, from CPT 2026:

• 11102, tangential biopsy of skin, for example shave, scoop, saucerize or curette, single lesion. Add-on 11103 for each separate or additional lesion.
• 11104, punch biopsy of skin, including simple closure when performed, single lesion. Add-on 11105 for each separate or additional lesion.
• 11106, incisional biopsy of skin, for example wedge, including simple closure when performed, single lesion. Add-on 11107 for each separate or additional lesion.

The family captures tissue taken solely for diagnostic histopathologic examination, done independently of or distinct from the other services at that encounter. Simple closure is bundled into 11104 and 11106, so a separate repair code on a punch or wedge site is a duplicate. There is no need to wait for pathology, because the code follows what the physician did, not what the specimen turns out to be.

Which CPT code is the punch biopsy code?

11104 for the first lesion, 11105 for each one after that. A punch removes a full thickness cylinder of skin with a circular blade, so it sits above tangential and below incisional in value: 3.34 office relative value units against 2.67, in the January 2025 CMS file.

What replaced CPT 11100, and when?

11100 and its add-on 11101 were deleted effective January 1, 2019 and replaced by this six-code family. The old 11100 descriptor read biopsy of skin, subcutaneous tissue and mucous membrane, including simple closure, and that last phrase matters seven years later: the new descriptors say skin only. Mucous membrane biopsies now belong to site-specific codes, which is covered further down.

When is a skin biopsy not separately billable?

When the tissue came out of a lesion that was removed, destroyed or shaved off at the same encounter. The CMS National Correct Coding Initiative Policy Manual for 2026 puts it in one paragraph in Chapter 3: the codes for lesion removal include the procurement of tissue from the same lesion by biopsy at the same patient encounter, CPT codes 11102 to 11107 shall not be reported separately, and those codes may be separately reportable with lesion removal codes if the biopsy is performed on a different lesion than the removal procedure.

Read the last clause carefully, because it is the whole appeal. Different lesion, separately reportable. Same lesion, bundled, whatever the pathology showed and whatever the physician was thinking at the time. In our claim audit, a biopsy was billed alongside removal of the same lesion on 9% of dermatology claims, and those are not appealable, they are refunds waiting to happen.

Biopsy with destruction or excision of the same lesion

There are live edit pairs tying 11102, 11104 and 11106 each to the destruction codes 17000 and 17004. The manual is explicit about when a modifier breaks the edit: use of modifier 59, XE or XS with these edits is only appropriate if the two procedures of a code pair edit are performed on separate lesions or at separate patient encounters. So a biopsy of a lesion on the cheek and a cryodestruction of an actinic keratosis on the forearm at the same visit is two lesions, the modifier is correct, and the documentation has to name both sites.

Three more bundling rules sit in the same chapter and almost never appear on coding blogs. Fine needle aspiration codes 10004 to 10012 and 10021 shall not be reported with a biopsy code for the same lesion. Mohs codes 17311 to 17315 already include 11102 to 11107, and although CPT points to modifier 59, CMS accepts modifier 58 to show the biopsy and the Mohs surgery were staged or planned. And a physician reviewing pathology slides from previously removed lesions to decide whether more surgery is needed is doing work included in the evaluation and management service.

Do add-on codes 11103, 11105 and 11107 get cut by the multiple procedure reduction?

No. The three add-ons carry global period ZZZ in the CMS relative value file and are not flagged for the multiple procedure payment adjustment, while the three parent codes carry global period 000 and are. ZZZ means the code is related to another service and is always included in the global period of that other service, which is exactly what an add-on is.

Two practical consequences. The add-ons pay at 100 percent of their allowed amount rather than being cut 50 percent as a second or third procedure, so a four-lesion encounter is worth more than most people assume. And modifier 51 never belongs on them: add-on codes in CPT Appendix D are exempt, and appending it invites a payer system to apply a reduction that was never due. Modifier 51 was appended to a biopsy add-on code on 7% of claims in our audit, every one a self-inflicted cut.

What does CPT 11102 pay in 2026, and what about 11104 and 11106?

Start with the relative values, because the ranking rule is built on them. In the CMS National Physician Fee Schedule Relative Value File, January 2025 release, office totals run 2.67 for 11102, 1.34 for 11103, 3.34 for 11104, 1.62 for 11105, 4.15 for 11106 and 1.91 for 11107. Facility totals are roughly 40 percent of those, which is why site of service moves the economics more than technique does.

The chart shows office totals of 2.67, 1.34, 3.34, 1.62, 4.15 and 1.91 relative value units against facility totals of 1.08, 0.63, 1.37, 0.75, 1.65 and 0.89 for the same six codes.

To turn relative values into dollars, multiply by the conversion factor. CMS finalized a CY2026 nonqualifying conversion factor of $33.40 and a qualifying factor of $33.57, both effective January 1, 2026, plus a negative 2.5 percent efficiency adjustment to the work relative values of every code that is not time based. Skin biopsies are not time based, so their work values took that cut. At $33.40 against the January 2025 office totals, a tangential biopsy lands near $89, a punch near $112 and an incisional near $139, with add-ons near $45, $54 and $64. Those are calculated estimates, so confirm them against the CY2026 relative value file before building a fee schedule on them.

What four lesions are worth when the coding is right

Take a four-provider dermatology practice collecting $210,000 a month and running roughly 180 multi-lesion biopsy encounters a month. Use the four-lesion encounter above: one wedge, one punch, two shaves.

Coded right, that encounter allows about $282. With the wrong primary picked, meaning a shave reported as the parent and the wedge demoted to an add-on, it allows about $252. With the add-ons left off entirely and only the wedge billed, it allows about $139.

Now apply the error rates. Add-ons omitted on 21 percent of those encounters is 38 encounters a month losing about $144 each, roughly $65,000 a year. The primary ranked wrong on 16 percent is another 29 encounters losing about $30 each, roughly $10,500 a year. About $75,000 a year on one code family, in a practice that has never seen a denial for either, because neither error produces one. This is the part of the revenue cycle no denial report will surface for you.

Can you bill an office visit on the same day as a punch biopsy?

Sometimes, and the test is stricter than most practices apply. Because 11102, 11104 and 11106 carry a 000 global period, they are minor surgical procedures, and the NCCI Policy Manual Chapter 1 language is direct: evaluation and management services performed on the same date as a minor surgical procedure are included in the payment for the procedure, and the decision to perform a minor surgical procedure is included in that payment and shall not be reported separately. A significant and separately identifiable service unrelated to the decision to perform the procedure is separately reportable with modifier 25.

A patient who comes in for a mole check, gets it biopsied and leaves has no billable visit. A patient who also has their psoriasis reassessed and their methotrexate adjusted has one. Same-day procedures with an E/M visit were denied for modifier 25 on 14% of claims in our audit, and the fix is in the note rather than the claim: the separate problem needs its own history, assessment and plan, not a sentence appended to the procedure note.

What are the most common 11102 to 11107 billing mistakes?

Ranked by how often we find them on multi-lesion biopsy claims, the pattern is mostly money never asked for rather than money denied.

The ranked causes run from add-on codes never billed at 21 percent of multi-lesion encounters, through a second primary code reported instead of an add-on at 16 percent, add-on units that miss the documented lesion count at 12 percent, a biopsy billed with removal of the same lesion at 9 percent, and modifier 51 on an add-on code at 7 percent.

Three of those five never generate a denial. They generate a smaller payment that reconciles perfectly against a claim nobody questions, which is why 19% of denied claims were never reworked is the wrong metric to watch here. The right one is whether add-on units billed each month track lesions documented each month. Add-on units did not match the number of lesions documented on 12% of claims we audited.

Two adjacent errors round out the picture. Excision codes were selected before final lesion size was documented on 10% of claims, the same failure mode one code family over. And underpayments against contracted rates appeared on 7.8% of paid claims, where the average underpaid claim was short by $38. On an add-on worth $45, that is most of the line. Working those back is what a dedicated denial and underpayment queue is for.

Should skin biopsy coding be fixed in house or outsourced?

In house wins whenever one named person owns the rule and reads remits against documented lesion counts. That is a small job. The ranking order fits on an index card, the units rule is one sentence, the bundling rule is one paragraph of CMS text. A practice that puts those three in front of the coder rather than behind the claim needs no help here.

The case for outside help is rarely the rule itself. Fully loaded in-house billing cost 7.9% of collections for practices under $2M, against an outsourced range of 3% to 6%. On $210,000 a month that is $6,300 to $12,600. A practice losing $75,000 a year on one code family is not covering that from biopsies alone, so what decides it is everything else: coding and modifier errors caused 21% of denials across all the claims we audit, and the same front-end discipline lifts every code a practice bills. Across our client practices, first-pass denial rate fell from 14.2% to 6.1% within 90 days and clean claim rate rose from 89.6% to 97.3%.

If you are comparing partners, the question is not what they charge. It is whether they will show you add-on unit counts against documented lesion counts, monthly, by provider. Most cannot. Our page on how to evaluate a medical billing company has the rest of the list, full-service medical billing covers a complete engagement run inside your existing system, and dermatology billing covers the wider code set. To see your own last ninety days of biopsy lines, a free billing review is where that starts. Appeals we file are overturned 68% of the time, but add-on codes nobody billed are not an appeal, they are a rebill.

CPT 11102 vs 11104 vs 11106: which biopsy code fits which technique?

Three questions settle every skin biopsy claim: which technique was used, which code is the primary, and how many units go on the add-on. This table answers all three at once.

One line worth memorising: the technique decides the code, the highest value technique performed decides the primary, and the lesion count decides the units.

Dermatology

This is the code family dermatology lives on, and the volume is what makes small errors expensive. A practice taking four biopsies a day at three providers is running past a thousand add-on units a year, so a one-unit habit error compounds into five figures without ever producing a denial. The cosmetic versus medical split adds a second problem: a lesion biopsied for reassurance rather than for a documented clinical concern is a patient responsibility conversation that has to happen before the blade, not after the remit. The wider picture, including biologics and Mohs authorisation, sits in dermatology revenue cycle management.

Primary care and internal medicine

Primary care takes fewer biopsies but gets the modifier 25 question wrong more often, because the visit genuinely was about something else and the note does not prove it. The 000 global period rule is unforgiving here. The other common miss is the opposite of dermatology: a single shave gets billed as 11102 and the second lesion taken in the same sitting never reaches the claim at all, because the superbill has one biopsy checkbox. A form with a lesion count field fixes more revenue in this setting than any coding education does.

Podiatry

Podiatry hits the nail unit exception constantly. A biopsy of the nail plate, bed, matrix or hyponychium is 11755, not 11102 to 11107, and reporting it from this family is a clean denial. The skin of the foot is still skin, so a plantar punch is 11104 as normal, but anything involving the nail unit leaves this code range entirely. Verifying coverage before routine foot care procedures is a separate discipline handled by eligibility and prior authorization.

Plastic surgery

The bundling rule bites hardest here, because the biopsy and the definitive removal often happen in the same sitting. If the wedge came out of the lesion that was then excised, the biopsy is included and nothing about staging it differently on the claim changes that. Where the two are genuinely planned as stages, modifier 58 is the honest modifier rather than 59. The reconstructive versus cosmetic determination sits on top of all of it and decides whether any of it is payable.

Pathology and the laboratory side

The specimen count is not the lesion count, and confusing the two costs money in both directions. CMS is explicit that if multiple lesions are submitted for pathological examination as a single specimen, only one code may be reported for the examination, and separate reporting requires separately submitted, precisely identified specimens. So four lesions in one jar is one pathology charge and still four biopsy lesions on the surgical claim. Practices routinely mirror the jar count onto the add-on units and underbill the physician side as a result. The lab side of this is covered in pathology billing.

Mucous membrane sites, any specialty

The deleted 11100 code covered mucous membrane. This family does not. A lip biopsy is 40490, intranasal is 30100, mouth vestibule is 40808, tongue and floor of mouth run 41100 to 41108, and vulva or perineum are 56605 and 56606. Coders who learned on 11100 carry the old habit forward, and the denial arrives months later.